As of August 1st, Saskatchewan is expanding coverage for Trikafta, which is a cystic fibrosis medication. Provincial coverage for this medication for CF patients 12 and older came into effect last October and now it is expanding to CF patients six and older who meet the medical criteria.

President and CEO of Cystic Fibrosis Canada, Kelly Grover, says this news will change the trajectory of the disease and the future for many children in Saskatchewan. She notes that Saskatchewan was one of the first provinces to fund the drug for those 12 and older, and she applauds the recognition of Trikafta’s extraordinary, transformative value, by expanding the coverage. Health Canada approved coverage for children ages six to 11 in April.

Without coverage, the cost of the drug is about $300,000 per patient annually, before confidential rebates.